SCHEMBL1900932

SCHEMBL1900932

CCS(=O)(=O)c1[c]cccc1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSIP1 O75475 1/20 0.38
COMT P21964 1/20 0.36
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32
CA7 P43166 1/20 0.32
CA9 Q16790 1/20 0.32
CA14 Q9ULX7 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC8 Q9BY41 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
TSHR P16473 2/20 0.31
HSD11B1 P28845 1/20 0.31
GAA P10253 1/20 0.31
MMP2 P08253 1/20 0.30
MMP9 P14780 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17291026 0.78 PSIP1 (0.39) PSIP1COMTGAAALDH1A1
SCHEMBL7471136 0.78 CDK2 (0.39) CA12CA1CA2CA7CA9
SCHEMBL483018 0.78 SMN1; SMN2 (0.34) COMTCA12CA2CA14TSHR
SCHEMBL9614697 0.74 PSIP1 (0.35) PSIP1COMTCYP1A2CYP2D6CYP2C9
SCHEMBL1900933 0.73 COMT (0.39) PSIP1COMTCYP1A2CYP2D6CYP2C9
SCHEMBL8012166 0.73 PSIP1 (0.42) PSIP1CA12CA2CA9CYP1A2
SCHEMBL5152547 0.69 GABRA1 (0.39) TSHRGAAGABRA1GABRB2ALDH1A1
SCHEMBL2206820 0.69 PTGS2 (0.37) CYP1A2TSHRALDH1A1
SCHEMBL28549866 0.69 PSIP1 (0.44) PSIP1COMTCA12CA1CA2
SCHEMBL672426 0.67 PSIP1 (0.48) PSIP1COMTCA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455477-B2 Therapeutic compounds MERCK SHARP & DOHME CORP. (US) 2013-06-04 US disclosed
US-20110207711-A1 Therapeutic Compounds MSD K.K. (JP) 2011-08-25 US disclosed
EP-2320907-A1 THERAPEUTIC COMPOUNDS Merck & Co., Inc. (US) 2011-05-18 EP disclosed
WO-2010017047-A1 THERAPEUTIC COMPOUNDS MERCK & CO., INC. (US) 2010-02-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207711-A1 Therapeutic Compounds WEE2, MARK3, WEE1 PSIP1 2668/4885COMT 3431/4885CA12 4877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.